Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies
-- Developing Exosome Diagnostics technology for use with QIAGEN's nucleic acid-targeted consumables and automation - with initial product launches targeted in 2014
-- Standardized, easy-to-use exosome workflows will offer superior testing solutions from basic research to personalized healthcare on widely available PCR, pyrosequencing and next-generation sequencing technologies
To read the full, original article click on this link: QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research - MarketWatch
